Pharma stocks have suffered post Pandemic
Five charts to start your day
Pfizer, once the darling of pandemic-era investors, is now facing a dramatic reversal of fortune. The pharma giant's stock has plummeted 46 percent from its peak, wiping out billions in market value.
Enter Starboard Value, an activist investor with a $1 billion stake and a plan to shake things up. They're even enlisting former Pfizer execs in their mission to revive the struggling stock.
But Pfizer's not alone in this post-pandemic hangover. BioNTech, Pfizer's vaccine partner, has lost two-thirds of its value. Moderna has haemorrhaged a staggering $170 billion in market cap.
